CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
← catalyst calendarSponsored by Ionis Pharmaceuticals, Inc. (industry) · IONS — their whole pipeline →. With AstraZeneca.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
1,438actual
Sites
142
Countries
Argentina, Australia, Austria +18
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-03-13 | actual | When the study began enrolling |
| Primary completion | Apr 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2019-10-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Interventions
- Drug: Eplontersen — also filed as ION-682884, IONIS-TTR-LRx
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFComposite Outcome of Cardiovascular (CV) Mortality and Recurrent CV Clinical Events up to Week 140
measured Baseline up to Week 140
Publications
- PMID 42104840 — linked by the registry
- PMID 38065307 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · IONS's whole pipeline · Catalyst calendar · Every registered study · What changed